{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T02:06:34Z","timestamp":1773799594796,"version":"3.50.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,1,27]],"date-time":"2015-01-27T00:00:00Z","timestamp":1422316800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1186\/s13063-014-0541-9","type":"journal-article","created":{"date-parts":[[2015,1,26]],"date-time":"2015-01-26T17:56:32Z","timestamp":1422294992000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":62,"title":["Meropenem versus piperacillin-tazobactam for definitive treatment of bloodstream infections due to ceftriaxone non-susceptible Escherichia coli and Klebsiella spp (the MERINO trial): study protocol for a randomised controlled trial"],"prefix":"10.1186","volume":"16","author":[{"given":"Patrick NA","family":"Harris","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anton Y","family":"Peleg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jon","family":"Iredell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul R","family":"Ingram","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Spiros","family":"Miyakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew J","family":"Stewardson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin A","family":"Rogers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emma S","family":"McBryde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason A","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeff","family":"Lipman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eugene","family":"Athan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanjoy K","family":"Paul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Baker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiffany","family":"Harris-Brown","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David L","family":"Paterson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,1,27]]},"reference":[{"issue":"7","key":"541_CR1","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1097\/01.CCM.0000129973.13104.2D","volume":"32","author":"J Cohen","year":"2004","unstructured":"Cohen J, Cristofaro P, Carlet J, Opal S. New method of classifying infections in critically ill patients. Crit Care Med. 2004;32(7):1510\u201326.","journal-title":"Crit Care Med"},{"issue":"3","key":"541_CR2","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/S1473-3099(08)70041-0","volume":"8","author":"JD Pitout","year":"2008","unstructured":"Pitout JD, Laupland KB. Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis. 2008;8(3):159\u201366.","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"541_CR3","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1128\/CMR.18.4.657-686.2005","volume":"18","author":"DL Paterson","year":"2005","unstructured":"Paterson DL, Bonomo RA. Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev. 2005;18(4):657\u201386.","journal-title":"Clin Microbiol Rev"},{"issue":"2","key":"541_CR4","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1093\/jac\/dkq412","volume":"66","author":"MEA Kraker de","year":"2011","unstructured":"de Kraker MEA, Wolkewitz M, Davey PG, Koller W, Berger J, Nagler J, et al. Burden of antimicrobial resistance in European hospitals: excess mortality and length of hospital stay associated with bloodstream infections due to Escherichia coli resistant to third-generation cephalosporins. J Antimicrob Chemother. 2011;66(2):398\u2013407.","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"541_CR5","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1086\/420816","volume":"39","author":"DL Paterson","year":"2004","unstructured":"Paterson DL, Ko WC, Von Gottberg A, Mohapatra S, Casellas JM, Goossens H, et al. Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum beta-lactamases. Clin Infect Dis. 2004;39(1):31\u20137.","journal-title":"Clin Infect Dis"},{"issue":"12","key":"541_CR6","doi-asserted-by":"publisher","first-page":"2793","DOI":"10.1093\/jac\/dks301","volume":"67","author":"KZ Vardakas","year":"2012","unstructured":"Vardakas KZ, Tansarli GS, Rafailidis PI, Falagas ME. Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum beta-lactamases: a systematic review and meta-analysis. J Antimicrob Chemother. 2012;67(12):2793\u2013803.","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"541_CR7","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1093\/cid\/cir790","volume":"54","author":"J Rodriguez-Bano","year":"2012","unstructured":"Rodriguez-Bano J, Navarro MD, Retamar P, Picon E, Pascual A. beta-Lactam\/beta-lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli: a post hoc analysis of prospective cohorts. Clin Infect Dis. 2012;54(2):167\u201374.","journal-title":"Clin Infect Dis"},{"key":"541_CR8","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1186\/1471-2334-12-245","volume":"12","author":"G Peralta","year":"2012","unstructured":"Peralta G, Lamelo M, Alvarez-Garcia P, Velasco M, Delgado A, Horcajada JP, et al. Impact of empirical treatment in extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp. bacteremia. A multicentric cohort study. BMC Infect Dis. 2012;12:245.","journal-title":"BMC Infect Dis"},{"issue":"10","key":"541_CR9","doi-asserted-by":"publisher","first-page":"5131","DOI":"10.1128\/AAC.00607-13","volume":"57","author":"M McLaughlin","year":"2013","unstructured":"McLaughlin M, Advincula MR, Malczynski M, Qi C, Bolon M, Scheetz MH. Correlations of antibiotic use and carbapenem resistance in Enterobacteriaceae. Antimicrob Agents Chemother. 2013;57(10):5131\u20133.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"541_CR10","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1093\/cid\/cir202","volume":"53","author":"N Gupta","year":"2011","unstructured":"Gupta N, Limbago BM, Patel JB, Kallen AJ. Carbapenem-resistant Enterobacteriaceae: epidemiology and prevention. Clin Infect Dis. 2011;53(1):60\u20137.","journal-title":"Clin Infect Dis"},{"issue":"12","key":"541_CR11","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1093\/cid\/cit152","volume":"56","author":"HW Boucher","year":"2013","unstructured":"Boucher HW, Talbot GH, Benjamin Jr DK, Bradley J, Guidos RJ, Jones RN, et al. Infectious Diseases Society of A: 10\u2009\u00d7\u2009\u203220 progress-development of new drugs active against gram-negative bacilli: an update from the Infectious Diseases Society of America. Clin Infect Dis. 2013;56(12):1685\u201394.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"541_CR12","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1128\/AAC.00826-13","volume":"58","author":"SM Drawz","year":"2014","unstructured":"Drawz SM, Papp-Wallace KM, Bonomo RA. New beta-lactamase inhibitors: a therapeutic renaissance in an MDR world. Antimicrob Agents Chemother. 2014;58(4):1835\u201346.","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"541_CR13","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.diagmicrobio.2009.01.018","volume":"64","author":"VH Tam","year":"2009","unstructured":"Tam VH, Ledesma KR, Chang KT, Wang TY, Quinn JP. Killing of Escherichia coli by beta-lactams at different inocula. Diagn Microbiol Infect Dis. 2009;64(2):166\u201371.","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"2","key":"541_CR14","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1128\/AAC.44.2.362-367.2000","volume":"44","author":"LB Rice","year":"2000","unstructured":"Rice LB, Carias LL, Hujer AM, Bonafede M, Hutton R, Hoyen C, et al. High-level expression of chromosomally encoded SHV-1 beta-lactamase and an outer membrane protein change confer resistance to ceftazidime and piperacillin-tazobactam in a clinical isolate of Klebsiella pneumoniae. Antimicrob Agents Chemother. 2000;44(2):362\u20137.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"541_CR15","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1128\/CMR.00036-08","volume":"22","author":"GA Jacoby","year":"2009","unstructured":"Jacoby GA. AmpC beta-lactamases. Clin Microbiol Rev. 2009;22(1):161\u201382.","journal-title":"Clin Microbiol Rev"},{"issue":"4","key":"541_CR16","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.jinf.2011.02.009","volume":"62","author":"YH Chen","year":"2011","unstructured":"Chen YH, Hsueh PR, Badal RE, Hawser SP, Hoban DJ, Bouchillon SK, et al. Antimicrobial susceptibility profiles of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections in the Asia-Pacific region according to currently established susceptibility interpretive criteria. J Infect. 2011;62(4):280\u201391.","journal-title":"J Infect"},{"issue":"4","key":"541_CR17","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1128\/CMR.05035-11","volume":"25","author":"LS Tzouvelekis","year":"2012","unstructured":"Tzouvelekis LS, Markogiannakis A, Psichogiou M, Tassios PT, Daikos GL. Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions. Clin Microbiol Rev. 2012;25(4):682\u2013707.","journal-title":"Clin Microbiol Rev"},{"issue":"2","key":"541_CR18","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1093\/cid\/cir790","volume":"54","author":"J Rodriguez-Bano","year":"2012","unstructured":"Rodriguez-Bano J, Navarro MD, Retamar P, Picon E, Pascual A. Extended-Spectrum Beta-Lactamases-Red Espanola de Investigacion en Patologia Infecciosa\/Grupo de Estudio de Infeccion Hospitalaria G. beta-Lactam\/beta-lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli: a post hoc analysis of prospective cohorts. Clin Infect Dis. 2012;54(2):167\u201374.","journal-title":"Clin Infect Dis"},{"issue":"24","key":"541_CR19","doi-asserted-by":"publisher","first-page":"2594","DOI":"10.1001\/jama.2012.87802","volume":"308","author":"G Piaggio","year":"2012","unstructured":"Piaggio G, Elbourne DR, Pocock SJ, Evans SJ, Altman DG, Group C. Reporting of noninferiority and equivalence randomized trials: extension of the CONSORT 2010 statement. JAMA. 2012;308(24):2594\u2013604.","journal-title":"JAMA"},{"key":"541_CR20","unstructured":"Breakpoint tables for interpretation of MICs and zone diameters version 4.0. Available from: http:\/\/www.eucast.org . Accessed 6th December 2014."},{"issue":"1","key":"541_CR21","doi-asserted-by":"publisher","first-page":"26","DOI":"10.7326\/0003-4819-140-1-200401060-00008","volume":"140","author":"DL Paterson","year":"2004","unstructured":"Paterson DL, Ko WC, Von Gottberg A, Mohapatra S, Casellas JM, Goossens H, et al. International prospective study of Klebsiella pneumoniae bacteremia: implications of extended-spectrum beta-lactamase production in nosocomial Infections. Ann Intern Med. 2004;140(1):26\u201332.","journal-title":"Ann Intern Med"},{"key":"541_CR22","doi-asserted-by":"crossref","DOI":"10.1201\/9781584889830","volume-title":"Sample size calculations in clinical research","author":"S-C Chow","year":"2007","unstructured":"Chow S-C, Hansheng W, Shao J. Sample size calculations in clinical research. 2nd ed. Boca Raton: Chapman Hall; 2007.","edition":"2"},{"key":"541_CR23","unstructured":"Harris PNA, Mo Y, Jureen R, Chew J, Ali J, Paterson DL, Tambyah PA. Meropenem and piperacillin-tazobactam have comparable outcomes in treatment of bloodstream infections caused by extended spectrum beta-lactamase producing E.coli and Klebsiellae. Abstract number 486, IDWeek. Philadelphia, PA: 8 to 12 October 2014. Available from: https:\/\/idsa.confex.com\/idsa\/2014\/webprogram\/Paper46679.html . Accessed 12th Jan 2015."},{"key":"541_CR24","unstructured":"EUCAST guidelines for detection of resistance mechanisms and specific resistances of clinical and\/or epidemiological importance. Available from: http:\/\/www.eucast.org\/fileadmin\/src\/media\/PDFs\/EUCAST_files\/Resistance_mechanisms\/EUCAST_detection_of_resistance_mechanisms_v1.0_20131211.pdf . Accessed 26th Jan 2015."},{"issue":"5","key":"541_CR25","doi-asserted-by":"publisher","first-page":"270","DOI":"10.5694\/mja12.11703","volume":"198","author":"DL Paterson","year":"2013","unstructured":"Paterson DL. Determining research priorities for clinician-initiated trials in infectious diseases. Med J Aust. 2013;198(5):270\u20132.","journal-title":"Med J Aust"},{"issue":"4","key":"541_CR26","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1056\/NEJMp1215093","volume":"368","author":"B Spellberg","year":"2013","unstructured":"Spellberg B, Bartlett JG, Gilbert DN. The future of antibiotics and resistance. N Engl J Med. 2013;368(4):299\u2013302.","journal-title":"N Engl J Med"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-014-0541-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13063-014-0541-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-014-0541-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-014-0541-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,20]],"date-time":"2019-08-20T04:17:23Z","timestamp":1566274643000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-014-0541-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1,27]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["541"],"URL":"https:\/\/doi.org\/10.1186\/s13063-014-0541-9","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,1,27]]},"assertion":[{"value":"21 September 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2014","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"24"}}